CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Vezins-de-levezou, France

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia

    Phase

    N/A

    Span

    523 weeks

    Sponsor

    Fundación Española de Hematología y Hemoterapía

    Torrelavega, Cantabria

    Recruiting

  • The Effectivenes of Non-invasive Neuromodulation in Adult Women With Primary Dysmenorrhea, Through the TENS Stimulation at Different Times of Mentrual Cycle in Each Group

    This RCT evaluates women of legal age, with pain greater than 3 on the NPRS scale, and whose menstrual cycle is regular, considered regular between 25-30 days. The sample will be divided into a cases group which in turn will be divided into 2 subgroups: stimulation intervention in women with dysmenorrhea during the bleeding phase (GI1), and in the luteal phase (GI2). On the other hand, the control group (CG) will be treated just like GI1, during the bleeding phase, but without the transcutaneous electrical nerve stimulation (TENS) transmitting the current. Initially, a screening questionnaire will be completed. Subsequently, a first assessment will be done to all included participants, which will be conducted by completing the Numerical Pain Scale (NPRS) in relation to their pain for 5 days, McGill Pain Questionnaire (MPQ), SF12 Health Survey, Specific Quality of life Questionnaire Related to Menstruation (CVM-22), Hospital Anxiety and Depression Scale (HADS) and Pain Catastrophizing Scale (PCS) and Pittsburgh Sleep Quality Index (PSQI), as well as pressure pain threshold measure (PPT). Participants will also be evaluated immediately after treatment and at the beginning of the next bleeding phase (next menstrual cycle), being 28 days after the intervention in the case of GI1 and GC, and 7 days after the intervention in the case of GI2. Regarding the intervention, the treatment plan to be done will be as follows: - GI1: TENS stimulation in the menstrual phase between days 25-28 (days before bleeding and where symptoms may begin) and 1-3 (first days of bleeding). - GI2: TENS stimulation in the follicular phase between days 17 to 24 of the menstrual cycle after the start of bleeding. - GC: Same procedure as GI1, but without TENS stimulation. This intervention is performed using a TENS with an asymmetric biphasic wave of 200 µs width, frequency of 100Hz and maximum intensity tolerated by the participant, adapting to avoid accommodation. The intervention will be carried out for 30 minutes, once a day, and 2 days a week, with 48-72 hours between both interventions. Regarding the electrodes, 4 adhesive electrodes (5.0x5.0) will be placed, 2 in the lower lumbar region and two in the parasacral region (S2-S4).

    Phase

    3

    Span

    22 weeks

    Sponsor

    Naiara Benítez Aramburu

    Torrelavega, Cantabria

    Recruiting

  • Transdiagnostic Group Cognitive Behavioral Therapy (PsicAP-A) for Adolescents With Emotional Disorders

    Phase

    N/A

    Span

    53 weeks

    Sponsor

    Instituto de Investigación Marqués de Valdecilla

    Torrelavega

    Recruiting

  • Treatment of Scars and Dysfunctions of the Pelvic Floor in Postpartum

    Phase

    N/A

    Span

    159 weeks

    Sponsor

    Universidad de León

    Torrelavega, Cantabria

    Recruiting

  • Computerized Registry of Patients With Venous Thromboembolism (RIETE)

    The RIETE Registry pretends the improvement of care of patients with thromboembolic disease. Very often the investigators pose serious doubts on how to manage a specific patient. Sometimes because it is a patient with thrombocytopenia, a pregnant woman, a patient with a recent cerebral bleeding or cerebral metastasis, a patient with gastroduodenal ulcer or hepatic cirrhosis. There is no clinical evidence about how the investigators should manage these patients and the investigators have to individualize its management. The bibliography available is not of much help. Only if the investigators have a database with a sufficient number of cases, they may be able to make evidence based decisions. This database on the Internet will allow the investigators to consult and obtain an immediate response when taking care of a patient who needs an individualized management. After introducing the patient the investigators will automatically obtain the data of all patients with similar clinical profiles. And this will help the investigators to identify high-risk patients and thus facilitate them preventing possible future complications.

    Phase

    N/A

    Span

    1401 weeks

    Sponsor

    Manuel Monreal

    Torrelavega, Cantabria

    Recruiting

1-5 of 5
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 703.538.7600
Toll Free: 888.838.5578

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information